HomeCompareOSGSY vs ABBV

OSGSY vs ABBV: Dividend Comparison 2026

OSGSY yields 1.65% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OSGSY wins by $15.36M in total portfolio value· pulled ahead in Year 5
10 years
OSGSY
OSGSY
● Live price
1.65%
Share price
$86.85
Annual div
$1.43
5Y div CAGR
96%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$15.46M
Annual income
$13,529,979.48
Full OSGSY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — OSGSY vs ABBV

📍 OSGSY pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOSGSYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OSGSY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OSGSY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OSGSY
Annual income on $10K today (after 15% tax)
$139.95/yr
After 10yr DRIP, annual income (after tax)
$11,500,482.56/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, OSGSY beats the other by $11,479,426.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OSGSY + ABBV for your $10,000?

OSGSY: 50%ABBV: 50%
100% ABBV50/50100% OSGSY
Portfolio after 10yr
$7.78M
Annual income
$6,777,375.62/yr
Blended yield
87.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

OSGSY
No analyst data
Altman Z
2.5
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OSGSY buys
0
ABBV buys
0
No recent congressional trades found for OSGSY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOSGSYABBV
Forward yield1.65%3.06%
Annual dividend / share$1.43$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR96%40.6%
Portfolio after 10y$15.46M$102.3K
Annual income after 10y$13,529,979.48$24,771.77
Total dividends collected$15.28M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OSGSY vs ABBV ($10,000, DRIP)

YearOSGSY PortfolioOSGSY Income/yrABBV PortfolioABBV Income/yrGap
1$11,023$322.72$11,550$430.00$527.00ABBV
2$12,446$651.60$13,472$627.96$1.0KABBV
3$14,665$1,347.70$15,906$926.08$1.2KABBV
4$18,600$2,908.81$19,071$1,382.55$471.00ABBV
5← crossover$26,660$6,758.16$23,302$2,095.81+$3.4KOSGSY
6$46,270$17,743.92$29,150$3,237.93+$17.1KOSGSY
7$105,920$56,410.54$37,536$5,121.41+$68.4KOSGSY
8$349,875$236,540.87$50,079$8,338.38+$299.8KOSGSY
9$1,805,611$1,431,244.56$69,753$14,065.80+$1.74MOSGSY
10$15,461,983$13,529,979.48$102,337$24,771.77+$15.36MOSGSY

OSGSY vs ABBV: Complete Analysis 2026

OSGSYStock

Osaka Gas Co., Ltd. provides gas, electricity, and other energy products and services in Japan and internationally. It operates through four segments: Domestic Energy/Gas, Domestic Energy/Electricity, International Energy, and Life & Business Solutions. The Domestic Energy/Gas segment manufactures, supplies, sells, and maintains gas; engages in the gas piping works, call center operation, temporary staffing, various research and consulting, engineering and construction, leasing, installment payments assistance, energy service, and other activities, as well as insurance agency business; operates and maintains LNG terminals and power plants; supplies heat; and generates, sells, and maintains electricity. This segment also sells liquefied nitrogen, liquefied oxygen, and liquefied argon; gas appliances, and housing equipment and appliances; LNG and LPG; and others. The Domestic Energy/Electricity segment supplies electric power. It generates and sells electricity from natural gas, wind, biomass, and solar resources. The International Energy segment engages in the LNG transport; development and investment of petroleum and natural gas; investment relating to energy supply business; and energy supply business. The Life & Business Solutions segment manufactures and sells fine materials, carbon material products, activated carbon, wood protective coatings, absorbent functional materials, and resin additives; develops, leases, manages, and sells real estate properties; develops software products; and provides computer-based data processing services. This segment is also involved in the operation, management, and maintenance of buildings and facilities, and others. The company was founded in 1897 and is headquartered in Osaka, Japan.

Full OSGSY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this OSGSY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OSGSY vs SCHDOSGSY vs JEPIOSGSY vs OOSGSY vs KOOSGSY vs MAINOSGSY vs JNJOSGSY vs MRKOSGSY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.